Lipid Nanoparticles: Production, Characterization and Stability

Shah, Rohan; Eldridge, Daniel S.; Palombo, Enzo A.; Harding, Ian H.

doi:10.1007/978-3-319-10711-0

Cited by 112 publications

(100 citation statements)

References 135 publications

(174 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The encapsulation of drugs within the solid lipidic matrix serves two important functions: i) to protect the drugs from chemical degradation, and ii) to modulate the drug release profile. Suspensions of SLNs have many of the desirable features of other nanostructures (biocompatibility, increased drug payload, controlled release, physical stability), but with reduced negative effects associated with those nanostructures (drug leakage, polymer, and solvent toxicity) . Cell culture studies have shown that the SLNs are nontoxic and easily taken up by human epithelial cells …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Structure Analysis of Solid Lipid Nanoparticles for Drug Delivery: A Combined USANS/SANS Study

Shah

Mata

Bryant

et al. 2018

Part & Part Syst Charact

View full text Add to dashboard Cite

Suspensions of solid lipid nanoparticles (SLNs) stabilized with emulsifiers have been extensively investigated (since the 1990s) as drug carriers, although details of their ultrastructure are poorly defined. Previously, a novel microwave‐assisted microemulsion‐based technique to prepare SLNs was reported. To understand the detailed internal structure of these SLNs, ultra‐small angle neutron scattering (USANS) and small angle neutron scattering (SANS) experiments are conducted on suspensions of hydrogenated stearic acid SLNs stabilized with hydrogenated Tween 20 surfactant in D2O. Together, SANS and USANS gives a combined Q range of 0.000047 to 0.6 Å−1 (corresponding to a size range of ≈1 nm–15 µm). This extended Q range allows a comprehensive understanding of the hierarchical structure of SLNs. The data are consistent with the multi‐length scale structure of SLNs having polydispersed large particles with roughened surfaces at the microscale level. At the nanoscale level, the results are consistent with the SLNs having an ellipsoidal shape intermediate between spheres and rods, with a crossover from mass fractals to surface fractals. The elucidation of this structure is particularly important given that the structure influences the stability and drug release properties of the nanoparticles. These results assist in the development of systems with desired shape and properties.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Ultrastructure generally relates to the interior of the particle and can relate to internal partitioning through, for example, a core‐shell structure. It can also relate to the formulation itself, including the particle and structures such as micelles, which may be simultaneously present …”

Section: Introductionmentioning

confidence: 99%

Structure Analysis of Solid Lipid Nanoparticles for Drug Delivery: A Combined USANS/SANS Study

Shah

Mata

Bryant

et al. 2018

Part & Part Syst Charact

View full text Add to dashboard Cite

show abstract

“…[31][32][33] Therefore, it is necessary to prove the solid state of the lipid in TMLGNs and investigate the influence of the incorporated drug on the melting behavior of lipid by DSC. DSC thermograms are shown in Figure 2C for pure MTO, CsA, GcNa raw material, blank excipients, physical mixture of drug and excipients, and lyophilized MTO-TMLGNs.…”

Section: Results and Discussion Characterization Of Tmlgnsmentioning

confidence: 99%

Synergistic and complete reversal of the multidrug resistance of mitoxantrone hydrochloride by three-in-one multifunctional lipid-sodium glycocholate nanocarriers based on simultaneous BCRP and Bcl-2 inhibition

Ling¹,

Zhang²,

Zhang³

et al. 2016

IJN

View full text Add to dashboard Cite

Multidrug resistance (MDR) is a severe obstacle to successful chemotherapy due to its complicated nature that involves multiple mechanisms, such as drug efflux by transporters (P-glycoprotein and breast cancer resistance protein, BCRP) and anti-apoptotic defense (B-cell lymphoma, Bcl-2). To synergistically and completely reverse MDR by simultaneous inhibition of pump and non-pump cellular resistance, three-in-one multifunctional lipid-sodium glycocholate (GcNa) nanocarriers (TMLGNs) have been designed for controlled co-delivery of water-soluble cationic mitoxantrone hydrochloride (MTO), cyclosporine A (CsA – BCRP inhibitor), and GcNa (Bcl-2 inhibitor). GcNa and dextran sulfate were incorporated as anionic compounds to enhance the encapsulation efficiency of MTO (up to 97.8%±1.9%) and sustain the release of cationic MTO by electrostatic interaction. The results of a series of in vitro and in vivo investigations indicated that the TMLGNs were taken up by the resistant cancer cells by an endocytosis pathway that escaped the efflux induced by BCRP, and the simultaneous release of CsA with MTO further efficiently inhibited the efflux of the released MTO by BCRP; meanwhile GcNa induced the apoptosis process, and an associated synergistic antitumor activity and reversion of MDR were achieved because the reversal index was almost 1.0.

show abstract

“…Lipid nanoparticles made from lipids are especially attractive because of their enhanced biocompatibility imparted by the lipid. They are novel particulate drug delivery systems which have gained considerable interest since last decade [12] . During the last years, different materials have been entrapped into lipid nanoparticles, extending from lipophilic and hydrophilic molecules, including labile compounds, such as proteins and peptides [41,42,43] .…”

Section: Lipid Nanoparticlesmentioning

confidence: 99%

“…They are generally composed of lipids, surfactants and co-surfactants [12] . Lipid nanoparticles are alternative drug delivery systems to polymeric nanoparticles [13] .…”

Section: Introductionmentioning

confidence: 99%

Lipid Nanoparticles for Ocular Drug Delivery

Okur

Gökçe

2015

International Journal of Ophthalmic Research

View full text Add to dashboard Cite

Despite numerous scientific efforts, efficient ocular drug delivery remains a challenge for pharmaceutical scientists. Delivery of ophthalmic drugs to the targeted ocular tissues is limited by many precorneal, dynamic and static ocular barriers. The anatomy, physiology and biochemistry of the eye render this organ exquisitely impervious to foreign substances. One of the promising strategies nowadays is the use of colloidal carrier systems characterized by a submicron-meter size. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) represent promising alternatives to conventional and very popular ocular carrier systems.

show abstract

Lipid Nanoparticles: Production, Characterization and Stability

Cited by 112 publications

References 135 publications

Structure Analysis of Solid Lipid Nanoparticles for Drug Delivery: A Combined USANS/SANS Study

Structure Analysis of Solid Lipid Nanoparticles for Drug Delivery: A Combined USANS/SANS Study

Synergistic and complete reversal of the multidrug resistance of mitoxantrone hydrochloride by three-in-one multifunctional lipid-sodium glycocholate nanocarriers based on simultaneous BCRP and Bcl-2 inhibition

Lipid Nanoparticles for Ocular Drug Delivery

Contact Info

Product

Resources

About